IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Caligan Partners LP

Q2 2025 Holdings

Filed 2025-08-14 | 17 holdings | $520.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Verona Pharma PLC(VRNA)SPONSORED ADS925050106$135.9M1,436,87826.1%
Liquidia Corporation(LQDA)COM NEW53635D202$101.2M8,118,89219.4%
Exelixis Inc(EXEL)COM30161Q104$67.2M1,525,73012.9%
Agios Pharmaceuticals Inc(AGIO)COM00847X104$35.6M1,071,2586.8%
Merus N VCOMN5749R100$34.6M656,9996.6%
Evolus Inc(EOLS)COM30052C107$30.8M3,341,9705.9%
Mineralys Therapeutics Inc(MLYS)COM603170101$27.3M2,017,3525.2%
Revolution Medicines Inc(RVMD)COM76155X100$23.4M636,8354.5%
Anika Therapeutics Inc(ANIK)COM035255108$15.2M1,435,1302.9%
Abivax SA(ABVX)SPONSORED ADS00370M103$12.8M1,674,4002.5%
Y-Mabs Therapeutics Inc(YMABUSD)COM984241109$10.6M2,342,6092.0%
Rezolute Inc(RZLT)COM NEW76200L309$6.9M1,543,0141.3%
Biocryst Pharmaceuticals Inc(BCRX)COM09058V103$5.7M638,9081.1%
Sellas Life Sciences Group I(SLS)CallCOM NEW81642T209$5.0M2,300,0001.0%
Verrica Pharmaceuticals IncCOM92511W108$4.9M9,239,1190.9%
Tyra Biosciences Inc(TYRA)COM90240B106$1.8M189,9500.3%
Aura Biosciences Inc(AURA)COM05153U107$1.3M200,0000.2%